Pharming Group PHAR

Richard Peters, MD, PhD. Richard has served as Chairman of Pharming's Board of Directors since September 25, 2023, and is a member of the Remuneration, Corporate Governance and Transaction committees. He brings more than 30 years of experience across life sciences leadership and academia, including as Global Head, Rare Diseases at Sanofi Genzyme and CEO of two Nasdaq-listed biotechnology companies, Merrimack Pharmaceuticals and Yumanity Therapeutics. Richard also serves as a Non-Executive Director of Aprea Therapeutics, Founder and Executive Chairman of TellBio, and a corporate advisor to Aura Biosciences. Earlier in his career, he held medical leadership roles at Amgen, Onyx Pharmaceuticals, Genzyme and Sanofi, and is a founder of X4 Therapeutics. He completed internal medicine training at Massachusetts General Hospital and a Howard Hughes post-doctoral fellowship at Harvard Medical School. He holds an M.D. and a Ph.D. in Pharmacology from the Medical University of South Carolina and began his medical studies at the Universite Catholique de Louvain in Belgium.

Barbara Yanni, JD, LLM.. Barbara has served as a Non-Executive Director since December 2020 and is the Chair of the Transaction Committee, and a member of the Remuneration and Corporate Governance committees. She brings deep expertise in licensing, corporate development, and healthcare strategy and finance. Barbara currently serves on the Board of Directors of Trevena, Inc., and two private biotechnology companies, Mesentech and Delsona Therapeutics. She previously served on the boards of several biotechnology companies including Oncorus, Inc. (2021-2023) and Vaccinex (2015-2025). She spent nearly three decades at Merck & Co., including as Vice President and Chief Licensing Officer (2001-2014), after earlier roles spanning corporate development, financial evaluation, and tax strategy. She began her career as a tax lawyer in New York City. She earned a J.D. from Stanford Law School and an A.B. from Wellesley College, and holds an LL.M. in Taxation from New York University.

Jabine van der Meijs, PharmD, MSc, ACMA/CGMA. Jabine has served as a Non-Executive Director since May 2021. She is Chair of the Corporate Governance Committee and a member of the Audit and Remuneration committees. She brings more than 30 years of senior leadership experience across finance, strategy and HR in global energy and airport management, with executive roles in the Netherlands, Scotland, England, Brunei and Australia. She previously served as Executive Vice President and CFO of Royal Schiphol Group (2017-2021) and spent 25 years at Royal Dutch Shell, including as VP Finance Projects for Shell's Projects & Technology business. Jabine is a Non-Executive Director at VFS Global AG and Grundfos Holding A/S and serves on the Supervisory Boards of Chane and the Centre for Human Drug Research. She holds a PharmD and an MSc (Pharmacy) from Utrecht University and is ACMA/CGMA qualified.

Leonard Kruimer,MBA, CPA. Leonard has served as a Non-Executive Director since May 2021. He is Chair of the Audit Committee and a member of the Transaction Committee. He brings more than 40 years of experience in corporate finance, planning and strategy, including 25 years in senior executive roles within private and publicly listed biotechnology companies. Leonard currently serves as Chairman of the Board at BioInvent International AB and serves as a board member of Zealand Pharma A/S and Basilea Pharmaceutica. He is also a Director of AI Global Investments (Netherlands) PCC Ltd. He previously served as CFO of Crucell N.V. (1997-2011) and held earlier roles including Managing Director at TIP Trailer (GE Capital), consultant at McKinsey & Company, and auditor at Price Waterhouse & Company in New York. He holds an MBA from Harvard Business School, a BBA from the University of Massachusetts Amherst, and is a Certified Public Accountant in New York State.

Mark Pykett, PhD, VMD, MBA. Mark has served as a Non-Executive Director since December 2020. He is Vice Chairman of the Board and a member of the Audit and Transaction committees. He brings more than 30 years of leadership experience across the biotechnology sector, spanning scientific, operational, and executive roles. Mark is currently Chief Executive Officer and Director of Orogen Therapeutics and serves on the Board of the private company Myopax. He previously served as President and Chief Executive Officer of Myrtelle, Inc., Chief Scientific Officer of PTC Therapeutics, and President and Chief Executive Officer of Agilis Biotherapeutics until its acquisition by PTC Therapeutics in 2018. Earlier roles include CEO of Navidea Biopharmaceuticals and senior leadership positions at Alseres Pharmaceuticals, Cygenics, and Cytomatrix. He holds a Ph.D. in Molecular Biology and a V.M.D. from the University of Pennsylvania, a B.A. in Biology from Amherst College, and an MBA from Northeastern University.

Elaine Sullivan, PhD. Elaine has served as a Non-Executive Director since June 2025. She is Chair of the Remuneration Committee and a member of the Audit Committee. She brings more than 25 years of international experience in the pharmaceutical and biotechnology industry, spanning R&D leadership, business development, and company creation. Elaine currently serves as a Non-Executive Director at Zealand Pharma A/S, Senior Non-Executive Director at hVIVO, and a Non-Executive Director of Ochre Bio. She has extensive international board experience across public biotechnology companies in Europe, including Sweden, Norway, Denmark, Germany and the United Kingdom. She previously co-founded Carrick Therapeutics and served as its CEO. Earlier in her career, she held senior global R&D leadership roles at Eli Lilly and AstraZeneca, including Vice President, Global External R&D at Lilly and Vice President and Head of New Opportunities at AstraZeneca. Elaine holds a PhD in Molecular Virology from the University of Edinburgh and a BSc (Hons) in Molecular Biology from the University of Glasgow.

Ines Bernal. Ines has served as Pharming's Chief People Officer since December 2024. She leads the Pharming's global people and culture strategy, overseeing talent, leadership development, organizational effectiveness, and core HR capabilities-supporting teams to do their best work in service of patients. Ines brings more than 25 years of human resources leadership across global organizations. Prior to joining Pharming, she was Global Vice President, Human Resources at Celanese Corporation. Earlier, she held senior HR roles across a range of industries, including GlaxoSmithKline, Yum! Restaurants (KFC, Taco Bell, Pizza Hut), and The Boeing Company. Ines holds a postgraduate degree in Business Economics and Strategic Human Resources and a bachelor's degree in Industrial Relations and Human Resources from the University of New South Wales in Sydney, Australia.

Leverne Marsh, BPharm. Appointed Chief Commercial Officer in January 2026, Leverne leads Pharming's global commercial strategy across market access, marketing, sales, and lifecycle management. She combines deep commercial expertise with practical experience applying AI and analytics to shape customer insight, using those skills to strengthen the connection between Pharming and the patients it serves. Leverne brings nearly 30 years of life-sciences commercial leadership. She has held senior roles at Novartis, where she led major product launches and served as Chief Product Officer and Head of Strategy, and at Dexcom, where she was Executive Vice President, Marketing, driving growth and international expansion. A trained pharmacist, Leverne began her career in pharmacy and holds a BPharm from the University of Port Elizabeth, South Africa.

Kenneth Lynard, MSc, EMBA. Since October 2025, Kenneth has served as Chief Financial Officer, or CFO, of Pharming. Kenneth brings nearly three decades of international finance leadership, including more than 20 years in the global life sciences industry. He has held senior finance roles across the United States and Europe, supporting both established pharmaceutical companies and growth-stage biopharmaceutical organizations. Prior to joining Pharming, Kenneth served as CFO of Schoeller Allibert and previously held CFO positions at Zentiva and Affidea, both Private Equity backed companies. Earlier in his career at Gilead Sciences, he served as Senior Vice President Finance for Global Commercial Operations, R&D, and Manufacturing, contributing to a period of significant transformation and expansion into new therapeutic areas and markets. Kenneth began his career in public accounting at Arthur Andersen before moving into senior finance leadership roles at Medtronic, Coloplast, and Superfos. He holds a Master of Science (MSc) in Business Economics and Auditing from Copenhagen Business School and an Executive MBA from IMD in Lausanne, Switzerland.

Anurag Relan, MD, MPH. Anurag Relan has been an integral part of Pharming for nearly two decades and was appointed Chief Medical Officer in June 2021. He leads the Pharming's global medical strategy, including clinical development, regulatory engagement, patient safety, and medical affairs. Previously, as Vice President of Clinical Research and Medical Affairs, Anurag began his career in clinical practice and academic medicine, teaching residents and medical students at the University of California, Los Angeles Medical Center, and he continues to practice as a physician. He has co-authored more than 30 publications in leading peer-reviewed medical journals, many focused on hereditary angioedema and rare disease. He holds an M.D. and a Master of Public Health (M.P.H.) from the University of California, Los Angeles, and a bachelor's degree in economics from the University of California, Berkeley.

Ruud van Outersterp. Appointed Chief Ethics and Compliance Officer in 2021, Ruud's role was updated in 2025 to Chief Legal and Compliance Officer and Company Secretary. He leads Pharming's global legal, compliance, and governance activities, ensuring Pharming operates with integrity across drug development and commercialization. Ruud first joined Pharming in 2020 as Company Secretary, and held that role until April 2022, strengthening corporate governance, board processes, and regulatory compliance. He brings more than 35 years of legal leadership experience across financial services, aerospace, and life sciences. Prior to Pharming, he held several senior roles at ABN AMRO and its predecessors, including Global Head of Legal and Company Secretary. In addition to his executive role, Ruud serves on the Supervisory Board of a Dutch healthcare institution providing a broad range of care services, primarily to elderly individuals and people with physical disabilities, and he teaches corporate governance at the Governance Academy in the Netherlands. He holds a Master of Laws (LLM) from the Vrije Universiteit Amsterdam.

Mireille Sanders, MSc. Appointed Chief Operations Officer in 2020, Mireille oversees Pharming's end-to-end operations, from development and manufacturing to quality and distribution of commercial and clinical supplies. Mireille joined Pharming as Senior Vice President of Operations in 2019. She brings 30 years of operational leadership across the life-sciences sector, including senior roles at Janssen Pharmaceuticals (Head of Clinical Supply Chain Strategic Management and Systems) and MSD/Merck. Mireille also represents Pharming on the Supervisory Board of BioConnection, a Netherlands-based CDMO specializing in sterile injectable manufacturing. She holds an MSc in Chemical Engineering from the Technical University of Eindhoven (TU/e), the Netherlands.

Maryana Reurings-Tsiganko, MBA, CIA, CISA, CFE. Appointed Vice President, Strategy & Operations in November 2025, Maryana serves as a strategy partner to Pharming's leadership team. She oversees the development and execution of the company's long-term strategy and leads key cross-functional initiatives that strengthen how the organization operates and delivers. Maryana joined Pharming in May 2021 and has held several leadership roles across the business, most recently serving as Interim Head of Finance and IT and as Program Director for end-to-end process transformation. She brings more than 15 years of experience across corporate finance, strategic operations, risk management, IT security, and internal audit and control, with prior senior roles at Sherwin Williams, Avery Dennison, OCI N.V., PNC, and KeyBank. Maryana holds an MBA with a focus in Finance and Supply Chain and a BA in International Business from Cleveland State University (Ohio, U.S.). She also holds multiple professional certifications, including Certified Internal Auditor (CIA), Certified Information Systems Auditor (CISA), and Certified Fraud Examiner (CFE).

Alexander Breidenbach, PhD, MBA. Appointed Chief Business Officer in September 2023, Alexander leads Pharming's growth strategy and business development agenda. He is responsible for evaluating and executing partnerships and transactions that strengthen Pharming's portfolio and long-term value. Alexander brings more than 25 years of global experience across partnering, R&D, and management in the biosciences sector. Prior to joining Pharming, he served as Chief Business and Chief Development Officer at ACM Biosciences AG and held a range of senior leadership roles at Roche Partnering, where he worked across global business development, due diligence, and deal execution, including in rare disease. Earlier in his career, he began as a senior scientist in pharmacology, grounding his work in the science behind the assets he evaluates. He holds a PhD in Biochemistry from the Tierarztliche Hochschule (University of Veterinary Medicine) Hannover, Germany, and an MBA from ESSEC Paris and Mannheim Business School.

Fabrice Chouraqui, PharmD, MBA. Appointed Chief Executive Officer and Executive Director in March 2025, Fabrice is responsible for Pharming's strategy and day-to-day operations, guiding Pharming's continued growth as a global rare disease company. Fabrice also serves as an independent Board member of OranoMed. Fabrice brings more than 30 years of global biopharma experience across R&D, commercialization, and venture-backed innovation. Prior to joining Pharming, he was a CEO-Partner at Flagship Pioneering and served as Chief Executive Officer of Cellarity, Inc. He spent a decade at Novartis, including as President of Novartis Pharmaceuticals USA, and held senior global and regional leadership roles. Earlier in his career, he held international leadership positions at Bristol-Myers Squibb in Europe and across Asia-Pacific, after beginning in research and development roles within the Sanofi legacy organization. He holds an MBA from INSEAD, a Doctorate in Pharmacy, a postgraduate degree in Quality Assurance of Medicines, and an MSc in Biological and Medicinal Sciences from Universite Paris Cite (University Paris V).